<DOC>
	<DOCNO>NCT01042808</DOCNO>
	<brief_summary>This survey conduct prepare application material re-examination Pharmaceutical Affairs Laws Enforcement Regulation , aim reconfirm clinical usefulness Isentress collect safety efficacy information usual practice accord Re-examination Regulation New Drugs . Post-marketing survey consider applicable clinical trial thus result survey post conclusion . The result submit public health official require applicable national international law .</brief_summary>
	<brief_title>Isentress Re-examination Study ( MK-0518-115 )</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>HIV1 Infected Adults Treated Isentress 400 mg tablet within local label enrollment period Contraindication Isentress accord local label</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>